Jazz Pharmaceuticals plc(JAZZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | 14.89 | EPS (ttm) | 14.5 | Insider Own | 3.94% | Shs Outstand | 64.8M | Perf Week | 0.93% |
| Market Cap | 14.02B | Forward P/E | 8.32 | EPS next Y | 84.54% | Insider Trans | -4.95% | Shs Float | 62.4M | Perf Month | -7.31% |
| Enterprise Value | 16.23B | PEG | 0.16 | EPS next Q | -4.05 | Inst Own | 101.21% | Short Float | 9.4% | Perf Quarter | -14.15% |
| Income | 0.94B | P/S | 3.05 | EPS this Y | 67.93% | Inst Trans | -1.28% | Short Ratio | 6.61 | Perf Half Y | 6.54% |
| Sales | 4.60B | P/B | 2.91 | EPS next 5Y | 50.59% | ROA | 8.54% | Short Interest | 5.86M | Perf YTD | 27.05% |
| Book/sh | 74.1 | P/C | 6.37 | EPS past 3/5Y | -17.69% - | ROE | 22.11% | 52W High | -18.92% ($266.38) | Perf Year | 58.46% |
| Cash/sh | 33.89 | P/FCF | 8.81 | Sales past 3/5Y | 5.26% 12.54% | ROIC | 11.5% | 52W Low | 67.69% ($128.80) | Perf 3Y | 72.84% |
| Dividend Est. | - | EV/EBITDA | 9.7 | EPS Y/Y TTM | 331.22% | Gross Margin | 73.63% | Volatility(W/M) | 3.15% 3.17% | Perf 5Y | 62.34% |
| Dividend TTM | - | EV/Sales | 3.53 | Sales Y/Y TTM | 12.59% | Oper. Margin | 20.76% | ATR (14) | 6.58 | Perf 10Y | 90.12% |
| Dividend Ex-Date | - | Quick Ratio | 1.58 | EPS Q/Q | 123.66% | Profit Margin | 20.45% | RSI (14) | 46.38 | Recom | 1.42 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.78 | Sales Q/Q | 15.55% | SMA20 | 0.34% ($215.25) | Beta | 0.38 | Target Price | $298.71 |
| Payout | - | Debt/Eq | 0.92 | Earnings | 2026/11/2 | SMA50 | -6.89% ($231.96) | Rel Volume | 1.37 | Prev Close | $207.83 |
| Employees | 2890 | LT Debt/Eq | 0.7 | EPS/Sales Surpr. | -7.53% 8.42% | SMA200 | -0.3% ($216.63) | Avg Volume(3M) | 0.89M | Price | $215.98 |
| IPO | 2007/6/1 | Option/Short | Yes/Yes | Trades | 17015 | Volume | 1,215,146 | Change | 3.92% |
An Ireland-based biopharmaceutical company that develops and sells neuroscience treatments for sleep disorders and epilepsy, as well as oncology drugs, generating stable revenue through key products such as Xywav and Epidiolex.
Over the past 1 year, roughly in the middle
19% below its 1-year high.
Traded more than usual. That is 137% of its average volume.
Next earnings report: November 2
2 days to go.
JAZZ makes money exceptionally well
Of every $100 in sales, $20.76 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.9% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $832. Peers typically go for $1,965. Compared with its own 2-year average, it is 14% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +62.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 101.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #18 of 597 in the industry
Based on market cap of $14B.
ASND#15 Ascendis Pharma A/S $17B PER 19.1 
HALO#16 Halozyme Therapeutics Inc $15B PER 39.1 
BBIO#17 BridgeBio Pharma Inc $15B PER - JAZZ#18 Jazz Pharmaceuticals plc $14B PER 14.9 
SMMT#19 Summit Therapeutics Inc $13B PER - 
FAQ
What kind of company is JAZZ?
JAZZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of JAZZ?
The market cap of JAZZ is approximately $14.0B, ranking 749 within its sector.
What is the P/E ratio of JAZZ?
JAZZ has a P/E ratio of approximately 14.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for JAZZ?
JAZZ has recorded a 52-week high of $266.38 and a low of $128.80.
